New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
08:30 EDTZTSZoetis growth should rebound in 2015, says Argus
Argus expects Zoetis' growth to rebound in 2015, as the animal medicine sector moves beyond temporary issues in the U.S. cattle and swine markets. The firm reiterates a Buy rating after the stock underperformed over the past quarter.
News For ZTS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
07:10 EDTZTSZoetis raises FY15 adjusted EPS view to $1.63-$1.68 from $1.61-$1.68
Consensus $1.66. Raises FY15 revenue view to $4.7B-$4.775B from $4.675B-$4.775B, consensus $4.74B. The company also reaffirmed its long-term outlook for 2016 and 2017.
07:07 EDTZTSZoetis reports Q2 adjusted EPS 43c, consensus 38c
Subscribe for More Information
August 3, 2015
16:32 EDTZTSZoetis receives conditional license from USDA
Zoetis announced that the U.S. Department of Agriculture has granted the company a conditional license for Canine Atopic Dermatitis Immunotherapeutic, an antibody therapy to help reduce clinical signs associated with atopic dermatitis in dogs. The USDA has communicated that all biological products for canine atopic dermatitis will be considered for conditional licensure only at this time. Zoetis said it is working with the USDA to obtain full licensure.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use